# Sridharan Gururangan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7329754/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 40<br>papers | 3,324<br>citations | 331670<br>21<br>h-index | 377865<br>34<br>g-index |
| 40<br>all docs | 40<br>docs citations | 40<br>times ranked | 4853<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Novel mutations target distinct subgroups of medulloblastoma. Nature, 2012, 488, 43-48. | 27.8 | 742 |
| 2 | Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehogâ€“Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. Journal of Clinical Oncology, 2015, 33, 2646-2654. | 1.6 | 368 |
| 3 | Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207. | 10.7 | 307 |
| 4 | Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495. | 10.7 | 274 |
| 5 | A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology, 2017, 19, 1135-1144. | 1.2 | 236 |
| 6 | Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2010, 28, 3069-3075. | 1.6 | 178 |
| 7 | Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomasâ€”a Pediatric Brain Tumor Consortium study. Neuro-Oncology, 2014, 16, 310-317. | 1.2 | 132 |
| 8 | Temozolomide in Children with progressive low-grade glioma1. Neuro-Oncology, 2007, 9, 161-168. | 1.2 | 127 |
| 9 | High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Children and Adults With Newly Diagnosed Pineoblastomas. Journal of Clinical Oncology, 2003, 21, 2187-2191. | 1.6 | 110 |
| 10 | Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835. | 1.6 | 106 |
| 11 | Phase II Study of Carboplatin in Children With Progressive Low-Grade Gliomas. Journal of Clinical Oncology, 2002, 20, 2951-2958. | 1.6 | 105 |
| 12 | Incidence and patterns of neuraxis metastases in children with diffuse pontine gliomaâ˜…. Journal of Neuro-Oncology, 2006, 77, 207-212. | 2.9 | 68 |
| 13 | Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathologica, 2020, 139, 223-241. | 7.7 | 65 |
| 14 | Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4. | 16.8 | 64 |
| 15 | Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-Oncology, 2008, 10, 745-751. | 1.2 | 61 |
| 16 | Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro-Oncology, 2012, 14, 1404-1412. | 1.2 | 50 |
| 17 | Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821. | 1.6 | 40 |
| 18 | [18F]Fluorodeoxyglucose-Positron Emission Tomography in Patients with Medulloblastoma. Neurosurgery, 2004, 55, 1280-1289. | 1.1 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. British Journal of Clinical Pharmacology, 2016, 81, 148-160. | 2.4 | 38 |
| 20 | Innovations in design and delivery of chemotherapy for brain tumors. Neuroimaging Clinics of North America, 2002, 12, 583-597. | 1.0 | 37 |
| 21 | Phase I Trial of Intrathecal Spartaject Busulfan in Children with Neoplastic Meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clinical Cancer Research, 2006, 12, 1540-1546. | 7.0 | 37 |
| 22 | Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro-Oncology, 2008, 10, 93-97. | 1.2 | 21 |
| 23 | Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research, 2008, 14, 1124-1130. | 7.0 | 20 |
| 24 | Additional Evidence of a Nonverbal Learning Disability in Survivors of Pediatric Brain Tumors. Children's Health Care, 2009, 38, 49-63. | 0.9 | 15 |
| 25 | Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). Cancer Immunology, Immunotherapy, 2017, 66, 1589-1595. | 4.2 | 15 |
| 26 | Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. International Journal of Radiation Oncology Biology Physics, 2015, 93, 47-53. | 0.8 | 14 |
| 27 | A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.. Journal of Clinical Oncology, 2014, 32, 10065-10065. | 1.6 | 10 |
| 28 | Characteristics of patients â‰¥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-Oncology, 2022, 24, 141-152. | 1.2 | 9 |
| 29 | Late Effects of Chemotherapy. Cancer Treatment and Research, 2009, 150, 43-65. | 0.5 | 9 |
| 30 | Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. Neuro-Oncology, 2022, 24, 821-833. | 1.2 | 9 |
| 31 | A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).. Journal of Clinical Oncology, 2013, 31, 2035-2035. | 1.6 | 8 |
| 32 | Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. Pediatric Blood and Cancer, 2015, 62, 1855-1858. | 1.5 | 6 |
| 33 | Childhood medulloblastoma: current and future treatment strategies. Expert Opinion on Orphan Drugs, 2015, 3, 1299-1317. | 0.8 | 2 |
| 34 | Acute neurotoxicity following vincristine due to Charcotâ€“Marieâ€“Tooth disease in a young child with medulloblastoma. Neuro-Oncology Practice, 2019, 6, 179-184. | 1.6 | 2 |
| 35 | EMBR-14. RECLASSIFICATION OF CENTRAL NERVOUS SYSTEM PRIMITIVE NEUROECTODERMAL TUMOR (CNS-PNET) INTO ENTITIES REFLECTS OUTCOME: RESULTS FROM THE PROSPECTIVE SJYC07 AND SJMB03 TRIALS. Neuro-Oncology, 2018, 20, i71-i72. | 1.2 | 0 |
| 36 | EMBR-13. FAVORABLE OUTCOMES IN CHILDREN WITH PINEOBLASTOMA TREATED WITH RISK-ADAPTED CRANIOSPINAL IRRADIATION AND CHEMOTHERAPY: RESULTS AND MOLECULAR ANALYSIS FROM THE SJYC07 AND SJMB03 TRIALS. Neuro-Oncology, 2018, 20, i71-i71. | 1.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | IMMU-08. reMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET). Neuro-Oncology, 2020, 22, iii361-iii361. | 1.2 | 0 |
| 38 | IMMU-26. DISEASE CONTROL IN A PEDIATRIC PATIENT WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) AND SOMATIC HIGH MICROSATELLITE INSTABILITY (MSI-H) WITH PD-1 INHIBITOR NIVOLUMAB (NIVO) ONLY AND NO FOCAL RADIOTHERAPY (RT). Neuro-Oncology, 2020, 22, iii365-iii365. | 1.2 | 0 |
| 39 | Advances in the diagnosis and treatment of malignant childhood brain tumors. Clinical Advances in Hematology and Oncology, 2007, 5, 120-2. | 0.3 | 0 |
| 40 | MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Neuro-Oncology, 2022, 24, i123-i124. | 1.2 | 0 |